Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes

Ryan C. Ungaro, Berkeley N. Limketkai, Camilla Bjørn Jensen, Clara Yzet, Kristine H. Allin, Manasi Agrawal, Thomas Ullman, Johan Burisch, Tine Jess, Jean Frederic Colombel

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint Dive into the research topics of 'Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes'. Together they form a unique fingerprint.

Medicine & Life Sciences